| 產(chǎn)品名稱 |
Enteric group 137 |
| 商品貨號(hào) |
B233584 |
| Strain Designations |
CDC 2411-97 |
| Application |
Produces extended spectrum beta-lactamase (ESBL) |
| Isolation |
Human urine, Chicago, IL, 1997 |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
freeze-dried |
| Preceptrol® |
no |
| Type Strain |
no |
| Antibiotic Resistance |
Resistant to ampicillin Resistant to aztreonam Resistant to cefazolin Resistant to ceftazidime Resistant to cephalothin Resistant to piperacillin Sensitive to ampicillin-sulbactam Sensitive to cefotetan Sensitive to imipenem Sensitive to piperacillin-tazobactam |
| Medium |
ATCC® Medium 18: Trypticase Soy Agar/Broth
|
| Growth Conditions |
Temperature: 37.0°C Atmosphere: aerobic |
| Name of Depositor |
NA Strockbine |
| Special Collection |
NCRR Contract |
| Chain of Custody |
ATCC <<--NA Strockbine<<--J.R. Warren |
| Year of Origin |
1997 |
| References |
Warren JR, et al. Outbreak of nosocomial infections due to extended-spectrum beta- lactamase-producing strains of enteric group 137, a new member of the family enterobacteriaceae closely related to citrobacter farmeri and citrobacter amalonaticus. J. Clin. Microbiol. 38: 3946-3952, 2000. PubMed: 11060050
|
